전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved157 programs
AntibodyCurated CoreFDAMerckApproved

pembrolizumab (Keytruda)

Multiple solid tumors · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1669Status Approved
AntibodyCurated CoreFDAJanssenApproved

daratumumab (Darzalex)

Multiple myeloma · CD38

#CD38#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 454Status Approved
AntibodyCurated CoreFDAJohnson & JohnsonApproved

teclistamab (Tecvayli, JNJ-64007957, teclistamab-cqyv)

Relapsed or refractory multiple myeloma · BCMA × CD3

#BCMACD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 132Status Approved
ADCCurated CoreFDAGSKMMAFApproved

belantamab mafodotin (Blenrep, GSK2857916)

Multiple myeloma · BCMA

#BCMA#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 78Status Discontinued
CGTCurated CoreFDAJohnson & JohnsonApproved

ciltacabtagene autoleucel (Carvykti, cilta-cel, LCAR-B38M, JNJ-68284528)

Relapsed or refractory multiple myeloma · BCMA

#BCMA#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 29Status Approved
AntibodyCurated CoreFDARegeneronApproved

linvoseltamab (Lynozyfic, REGN5458, linvoseltamab-gcpt)

Relapsed or refractory multiple myeloma after ≥4 prior lines including a PI, an IMiD, and an anti-CD38 antibody · BCMA × CD3

#BCMACD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 24Status Approved
CGTLimited DatastaleThomas Martin, MDPhase 1

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

Multiple Myeloma; Recurrent Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 211Status Discontinued
AntibodyCurated CorestaleRocheApproved

Tocilizumab (Tocilizumab)

Multiple Myeloma (MM); Multiple Myeloma Refractory · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Approved#BioJungboMoa-pick#Popular+5
Trials 161Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 131Status Active
ADCStandard DatabasestaleGSKcys-mcMMAFPhase 3

belantamab mafodotin (Blenrep, GSK2857916)

Primary Immune Thrombocytopenia (ITP) · Multiple Myeloma

#MultipleMyeloma#ADC#Phase3#Popular#antibody-drug-conjugate+4
Trials 73Status Recruiting
AntibodyLimited DatastaleGenentech, Inc.Phase 3

Tiragolumab (Tiragolumab)

Multiple Myeloma; Non-Hodgkin Lymphoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 65Status Active
CGTLimited DatastaleMalaysia Palm Oil BoardPhase 1

Interleukin (Interleukin)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#Popular#cell-gene-therapy+3
Trials 60Status Active
CGTStandard DatabasestaleCelgenePhase 2

ASCT (ASCT)

Multiple Myeloma; Newly Diagnosed · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 59Status Recruiting
AntibodyCurated CorestaleGenentech, Inc.Phase 2

Ocrelizumab (Ocrelizumab)

Rheumatoid Arthritis · Multiple Sclerosis

#MultipleSclerosis#Antibody#Phase2#BioJungboMoa-pick#Popular+4
Trials 58Status Discontinued
AntibodyLimited DatastalePfizerPhase 3

Elotuzumab (Elotuzumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 57Status Recruiting
CGTStandard DatabasestaleMinsk Scientific-Practical Cent…Phase 2

Anti-BCMA CAR-T cells (Anti-BCMA CAR-T cells)

Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Active
AntibodyCurated CorestaleIndapta Therapeutics, INC.Phase 3

Isatuximab (Isatuximab)

NHL; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#BioJungboMoa-pick#Popular+4
Trials 56Status Recruiting
CGTLimited DatastaleCarbiogene Therapeutics Co. Ltd.Phase 2

anti-BCMA CAR-T (anti-BCMA CAR-T)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Recruiting
AntibodyCurated CorestalePfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#BioJungboMoa-pick#Popular+4
Trials 54Status Recruiting
CGTLimited DatastaleInternational Brain Research Fo…Phase 2

Quercetin (Quercetin)

Recurrent Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 54Status Recruiting

1 / 8 pages

← PreviousNext →